Yale Cancer Center
M

Treatment Approach to ROS1 Rearranged NSCLC

By Yale Cancer Center FEATURING Michael Grant
By Yale Cancer Center FEATURING Michael Grant
476 views
October 19, 2023
On November 15, 2023, the FDA approved repotrectinib (brand name Augtyro) for locally advanced or metastatic ROS1-positive non-small cell lung cancer.
Comments 0
Login to view comments. Click here to Login

Featured Video

09:36
Johnson & Johnson

Mechanisms of Resistance in Locally Advanced or Metastatic EGFR+ NSC…

Feat. J. Heymach, M. Das

Featured Video

06:27
Johnson & Johnson

Challenges to Navigate in Locally Advanced or Metastatic EGFR+ NSCLC

Feat. M. Socinski, D. Waterhouse

Related Videos

27:06

WCLC 2024 Insights: Optimal Management of Malignant Pleural Effusion

Insights from 2024 WCLC

P. Lee

904 views
08:49

ESMO 2024 Insights: Treatment Rechallenge After Grade 1 Trastuzumab-…

2024 ESMO Annual Meeting Insights Hub

K. Natsuhara

794 views
08:49

The Use of IO Doublet in PD-L1-Negative NSCLC

David Carbone

2.6K views
26:38

Metastatic EGFRm NSCLC: 1L Therapy Options

University of Colorado Cancer Center

T. Patil

376 views
17:50

Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

AdventHealth

G. Sonpavde

1.9K views
36:14

ASCO® 2024 Lung Cancer Highlights: Top Abstracts Including BEAT-SC, …

2024 ASCO® Annual Meeting Insights Hub

B. Halmos

835 views
21:50

Multidisciplinary Panel Discussion: New Treatment Options for Surgic…

David Carbone

B. Stiles

277 views
12:42

Surveillance Imaging in Solid Tumors: More Complicated Than It Appea…

ecancer

C. Booth

207 views
09:52

WCLC 2024 Insights: Interstitial Lung Disease and Lung Cancer - How …

Insights from 2024 WCLC

S. Ikeda

322 views
07:32

WCLC 2024 Insights: MARIPOSA - Amivantamab + Lazertinib vs. Osimerti…

Insights from 2024 WCLC

S. Gadgeel

274 views
35:40

Year in Review: Lung Cancer

Balazs Halmos

2.6K views
16:10

ASCO® 2024 Lung Cancer Highlights: CROWN, LAURA, ADRIATIC, and PALOM…

2024 ASCO® Annual Meeting Insights Hub

L. Raez

683 views
19:15

ESMO 2024 Summary: EGFRm NSCLC Panel Discussion - MARIPOSA, PAPILLON…

ecancer

I. Gil-Bazo, M. Brandão, B. Besse, E. Felip

237 views
29:25

Hyperprogression in Cancer Treated With Immunotherapy

Northwestern Medicine Oncology and Hematology

Y. Chae

1.2K views
20:07

ESMO 2024 Summary: Developmental Therapeutics Highlights

2024 ESMO Annual Meeting Insights Hub

G. Sonpavde

261 views
02:41

Staging Disease: How Oncologists Stage NSCLC

GRACE

I. Dagogo-Jack, M. Das, C. Jeffrey Yang

596 views
03:55

Treatment Updates in Advanced and Metastatic NSCLC - Advances in Tho…

Total Health

J. Porter

157 views
15:49

New Frontiers in Oncology: Advanced Diagnostics and Therapeutics

Springer Healthcare IME

S. Peters

174 views
20:04

UChicago Medicine Best of ASCO® 2024: NSCLC

UChicago Medicine Annual Practice Updates in Hematology and Oncology

R. Thawani

274 views
15:40

New

Lazertinib in 1L EGFR-Mutant NSCLC: Unique Mechanism and Benefits of…

Mariam Alexander

270 views
AUTOPLAY